Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting

Documenti analoghi

• Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting
  di: Abdullahi, Adam, et al.
  Pubblicazione: (2018)
• Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir
  di: Baker, Jennifer, et al.
  Pubblicazione: (2010)
• The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
  di: Gupta, Nidhi, et al.
  Pubblicazione: (2014)
• Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection
  di: Uchitsubo, Keita, et al.
  Pubblicazione: (2020)
• Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection
  di: Zhang, Xiaoman, et al.
  Pubblicazione: (2019)